IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

By S. Nobusawa, Takuya Watanabe, P. Kleihues, H. Ohgaki. Clinical Cancer Research, 2009

712 citations recorded by the source corpus.

Subfields: Cell Biology, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/f2ee0c7b499cff3978ee295b502833a56872fa52

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

In Genetics

In Molecular Biology

Citations in the corpus

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas (2010, background): “It has been suggested that IDH1 mutant primary glioblastoma in fact represent secondary glioblastoma that rapidly evolved from lower grade precursor tumors and thus have not been diagnosed before [13].”
Survival in glioblastoma: a review on the impact of treatment modalities (2016, background): “Therefore, IDH1 mutation is currently considered a reliable and objective molecular marker for secondary GBM, although indistinguishable from primary GBM from a pathological perspective [15].”
Genetics of adult glioma. (2012, background): “Given the clinical characteristics of G-CIMPepositive proneural tumors, it is not surprising that they are strongly associated with IDH1 mutations (24,30).”
Epidemiologic and Molecular Prognostic Review of Glioblastoma (2014, background): “They are a selective molecular marker of secondary GBMs and distinguish them from primary GBMs (86, 97, 101).”
The Definition of Primary and Secondary Glioblastoma (2012, background): “of all glioblastomas at the population level (13) and for 6% to 13% in hospital-based studies (10, 12, 67, 68).”
Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas (2018, background): “For example, isocitrate dehydrogenase 1 and/or 2 (IDH1 and/or 2)–mutant glioblastomas demonstrate significantly improved survivorship compared with IDH wild-type glioblastomas (31 months versus 15 months).(2,3) Similarly, patients with anaplastic oligodendrogliomas with 1p/19q codeletion benefit fro”